Drug intelligence / Profile preview

mussel oil

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Mussel oil, often derived from the New Zealand green-lipped mussel (Perna canaliculus), is a natural product rich in omega-3 fatty acids (including EPA, DHA, and ETA), furan fatty acids, glycosaminoglycans, and antioxidants. It is primarily recognized for its anti-inflammatory properties, which are believed to stem from its ability to inhibit inflammatory pathways such as NF-κB, p38MAPK, cyclooxygenase (COX), and lipo-oxygenase (LOX) cascades. It has been investigated for its potential in preventing atherosclerosis and is widely used as a dietary supplement to support joint health, reduce inflammation, and modulate lipid profiles.

Other names: green-lipped mussel oilGLMO

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)VCAM1 (Vascular cell adhesion molecule 1)NOS2 (Nitric Oxide Synthase 2)

Beyond the preview

Go deeper on mussel oil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mussel oil.

Explore the full profile